This is a phase 3 study to evaluate the efficacy, safety and tolerability of a Clostridium Difficile (C-Diff) vaccine in adults 50 years of age and older. All study procedures and medication (vaccines) are provided to you at no cost and financial compensation up to $475.00 is available for your time and travel to the study site.
All information you provide is stored in a secure site, and cannot be released to any third party without your written and signed authorization.
Clostridium Difficile (C-Diff) is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from C-Difficile most commonly affects older adults in hospitals or in long-term care facilities and after the use of antibiotic medications.
Each year in the United States, about a half million people get sick from C-Difficile and in recent years the infections have become more frequent, severe and difficult to treat.